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http://www.biomedcentral.com/1471-2369/14/39RESEARCH ARTICLE Open AccessFibroblast growth factor-23 and calcium
phosphate product in young chronic kidney
disease patients: a cross-sectional study
Abeer Yasin1, Daisy Liu1, Luan Chau2, Joaquín Madrenas2,4 and Guido Filler1,2,3*Abstract
Background: Fibroblast growth factor-23 (FGF-23), a novel marker of bone disease in chronic kidney disease (CKD)
has been shown to correlate with vascular calcifications. We aimed to describe the effect of the calcium phosphate
product (Ca*P) on FGF-23 concentrations in children and young adults without confounding cardiovascular disease.
Methods: Pediatric and young adult patients with CKD stages I-V were recruited in this cross sectional study to
measure FGF-23, cystatin C, vitamin D-metabolites and other serum markers of bone metabolism. FGF-23 levels
were determined with an enzyme-linked immunosorbent assay. The association between FGF-23 and (Ca*P) was
assessed using non-parametric methods. Patients were divided into two age groups, less than 13 years of age and
greater than 13 years of age.
Results: This cross-sectional study measured serum FGF-23, in 81 patients (42 females, 51.9%) at London Health
Sciences Centre, aged 2 to 25 years, with various stages of CKD (Cystatin C estimated glomerular filtration rate,
eGFR=10.7-213.0 ml/min). For the whole entire group of patients, FGF-23 levels were found to correlate significantly
with age (Spearman r= 0.26, p=0.0198), Cystatin C eGFR (Spearman r=−0.40 p=0.0002), CKD stage (Spearman
r=0.457, p<0.0001), PTH (Spearman r=0.330, p=0.0039), ionized calcium (Spearman r=−0.330, p=0.0049), CysC
(Spearman r= 0.404, p=0.0002) and 1,25-dihydroxyvitamin D (Spearman r=−0.345, p=0.0034) concentrations. No
significant correlation was found between FGF-23 levels and calcium phosphate product (Spearman r= 0.164,
p=0.142). Upon classification of patients into two age groups, less than 13 years of age and more than 13 years of
age, correlational results differed significantly. FGF-23 correlated with CysC eGFR( Spearman r= −0.633, p<0.0001),
CKD stage (Spearman r=0.731, p<0.0001), phosphate (Spearman r= 0.557, p<0.0001), calcium phosphate product
(Spearman r=0.534, p<0.0001), 125(OH)2 Vit D (Spearman r=−0.631, p<0.0001), PTH (Spearman r= 0.475, p=0.0017)
and ionized calcium (Spearman r= −0.503, p=0.0015) only in the older group. The relationship between FGF-23 and
Ca*P for the older group could be expressed by the exponential model FGF-23= 38.15 e0.4625Ca*P.
Conclusion: Abnormal values of FGF-23 in adolescents and young adults with CKD correlate with Ca* P in the
absence of vascular calcifications, and may serve as a biomarker for the risk of cardiovascular calcifications.
Keywords: Chronic kidney disease, Fibroblast growth factor 23, Parathyroid hormone, Renal osteodystrophy,
Calcium phosphate product* Correspondence: guido.filler@lhsc.on.ca
1Department of Pediatrics, Children’s Hospital, London Health Science
Center, University of Western Ontario, 800 Commissioners Road East, London,
Ontario N6A 5W9, Canada
2Department of Microbiology and Immunology, and Medicine, and Center
for Human Immunology, Schulich School of Medicine & Dentistry, University
of Western Ontario, London, Ontario N6A 3K7, Canada
Full list of author information is available at the end of the article
© 2013 Yasin et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Yasin et al. BMC Nephrology 2013, 14:39 Page 2 of 8
http://www.biomedcentral.com/1471-2369/14/39Background
Fibroblast growth factor-23 (FGF-23) is a phosphaturic
hormone that increases in early chronic kidney disease
(CKD) before abnormalities in serum calcium, phosphate,
or parathyroid hormone (PTH) become apparent [1,2].
FGF-23 is thought to be produced by altered osteocyte
function in early CKD [3] and is elevated in patients with
end-stage kidney disease. FGF-23 has been linked with
mortality, vascular calcification, markers of bone turnover,
and left ventricular hypertrophy [4]. Cardiovascular disease
is a major cause of morbidity and mortality in adult patients
with end-stage renal disease receiving maintenance dialysis
[5]. Cardiovascular mortality is also a significant issue in
children and young adults with kidney disease, largely due
to vascular calcifications in the media of vessels [6,7]. As
higher phosphate levels are associated with vascular
calcifications, several studies have examined the role of
serum FGF-23 levels in phosphate metabolism and vascular
calcifications. Calcium phosphate products (Ca*P) >55 mg/
dl are independent predictors for coronary calcifications
[8]. However, there is no clear link between FGF-23 levels
and vascular calcifications. One study suggests that FGF-23
concentrations in blood are not associated with aortic
calcifications [9]. Other studies, however, have clearly linked
vascular calcifications with FGF-23 levels as an independent
risk factor, even across all CKD stages [10]. Certainly, vas-
cular calcification can be due to multiple etiologies such as
hypertension, hypercholesterolemia, as well as calcium
deposits; however, in children, the calcifications are mostly
related to Ca*P products and CKD [6]. In fact, children and
young adult patients with calcifications on dialysis have
higher serum phosphorus concentrations and a higher cal-
cium–phosphorus ion product in serum [11]. Desjardins
et al. suggest that plasma FGF-23 is an independent bio-
marker of vascular calcification in patients with various
CKD stages, including early stages [10]. FGF-23 has also
been associated with endothelial dysfunction [12,13].
In addition to increased FGF-23 production by osteo-
cytes [3], FGF-23 concentrations may also rise because of
accumulation in the serum secondary to decreased glom-
erular filtration. FGF-23 is a small molecular weight mo-
lecule, similar to that of Cystatin C (CysC), which also
accumulates in serum in patients with decreased renal
clearance [14]. Elevated FGF-23 levels have been reported
to suppress 1-alpha hydroxylase, worsen vitamin D defi-
ciency, and contribute to secondary hyperparathyroidism
[15]. Recently, there have also been reports that the renin-
angiotensin-aldosterone system (RAAS) interacts with
FGF-23 [16]. Few studies, however, have reported on the
prevalence of FGF-23 and other markers of bone mineral
metabolism disturbances in children with CKD [17,18].
There are many proposed mechanisms that link FGF-23
with cardiovascular morbidity and mortality. However,
there is no data on the relationship between FGF-23 andthe calcium phosphate product (Ca*P) in children and
young adults, where the confounding factors associated
with later age are less present.
The aim of the current study was to assess the rela-
tionship of FGF-23 with the Ca*P, CKD related mineral
bone abnormalities, and the prevalence of therapies to
correct them in a representative cohort of children and
young adults with CKD who do not have obvious vascu-
lar calcifications on planar x-ray. We were curious to
determine whether FGF-23 would correlate with the
Ca*P in the absence of vascular calcifications.
Methods
Study population
After obtaining ethical approval from the University of
Western Ontario Research Ethics Board (REB#16962E),
we recruited 81 pediatric and young adult patients with-
out evidence of cardiovascular disease in a cross-
sectional study. All patients between the ages of 2 and
40 years with CKD stage I-V at London Health Sciences
Centre, London, Ontario, were eligible. Written and
informed consent were obtained for each patient. Patients
with known vascular calcifications on chest x-rays were
not considered; in addition, renal transplant recipients
were excluded from this study.
In addition to routine blood work that was regularly
obtained for the monitoring of the CKD, we obtained
serum for FGF-23 and CysC levels in each case. We also
measured phosphate, calcium, ionized calcium, serum
albumin and total protein, bicarbonate, vitamin D
metabolites (1, 25-dihydroxy- and 25-hydroxyvitamin D),
and intact PTH levels, and urinary calcium to creatinine
ratio, using standard laboratory tests. CysC eGFR was
calculated using the “Filler-formula” [19,20]. Serum PTH
concentrations were assayed by a solid-phase, two-site
chemiluminescent enzyme-labelled immunometric assay
(Immunlite 2000 Intact PTH from Diagnostic Products
Corporation, Los Angeles, CA, USA). Ca*P was the simple
product of the total serum calcium and the serum
phosphate.
Analytical validation of FGF-23 assay
Serum FGF-23 levels were determined with a sandwich
enzyme-linked immunosorbent assay (ELISA) system using
two kinds of monoclonal antibodies requiring the simultan-
eous presence of both the N-terminal and C-terminal
portions of FGF-23 (Kainos Laboratories, Inc., Tokyo,
Japan; Millipore, St. Charles, Missouri, USA) following the
manufacturers’ instructions. In each antibody-coated well,
50 μL of serum sample with 50 μl of assay diluent were
added to each well. The plate was then incubated at room
temperature for 2 hours on a plate mixer. The plate was
washed 4 times and incubated with FGF-23 conjugate
mixing for 1 hour at room temperature. After another 4
Table 1 Breakdown of the various diagnoses groups overall and by CKD stage
Diagnosis Number Overall % % CKD stage I % CKD stage II % CKD stage III % CKD stage IV+V
Cystic 4 4.9% 2.3% 0.0% 7.7% 15.4%
Tubular 14 17.3% 20.5% 27.3% 15.4% 0.0%
Glomerular 34 42.0% 59.1% 36.4% 7.7% 23.1%
Uropathy 17 21.0% 13.6% 18.2% 23.1% 46.2%
Renal dysplasia 12 14.8% 4.5% 18.2% 46.2% 15.4%
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30 minutes. The signal was read in a microplate reader at
absorbance 450 nm within 10mins [21]. Inter-assay and
intra-assay coefficient of variation were 5.0 and 3.0%,
respectively. Cystatin C was measured using the Siemens
Healthcare nepholometric assay (PETIA) on a BN-Prospec
platform (Dade-Behring) [19,22].
Data analysis
Wherever possible, simple descriptive statistics were
used. Contiguous data were tested for normality using
the Shapiro-Wilk normality test. Normally distributed
data were analyzed using parametric methods (mean,
standard deviation, t-test, Pearson correlation), otherwiseTable 2 Patient characteristics, glomerular filtration rate (GFR
renal osteodystrophy by CKD stage
CKD stage CKD st
Number of patients 44
% of total patients 54.3
Median GFR (IQR 25th-75th percentile) 141.3 (105
Renal acidosis
Overall treated 11.4
Treated with bicarbonate (%) 2.3
Treated with potassium/sodium citrate (%) 9.1
Hypertension
Patients on any BP meds (%) 54.5
Patients on ACE-I or ARB (%) 43.2
Patients on non-ACE-I (diuretics, Ca-channel blocker etc.) (%) 18.2
Patients on multiple therapies (%) 22.7
Steroid therapy
% of patients on corticosteroid medications 18.2
% Renal osteodystrophy treated with
calcium containing phosphate binders 0.0
non-calcium containing phosphate binders 0.0
vitamin D analog 6.8
active vitamin D analog 0.0
Abnormally high PTH (N=1.6-6.9 pmol/L) 6.8
Abnormally high FGF-23 (N=10-50 pg/mL) 13.6
Abnormally high phosphate (N=0.80-1.33 mmol/L) 40.9
IQR=Inter quartile range, %=percent, BP=blood pressure, PTH=parathyroid hormonenonparametric methods were used (median, 25th per-
centile, 75th percentile, Mann Whitney t-test and
Spearman rank correlation). All statistical analysis was
performed using the statistical software GraphPad Prism,
version 5.0 (GraphPad Inc, San Diego, CA, U.S.A). A
p-value of < 0.05 was considered statistically significant.
Results
A total of 81 patients were included in the study.
Median age was 13.3 years (25th percentile 8.0, 75th per-
centile 17 years), and 42 patients (51.9%) were female.
Out of the 81 patients, 4 had hereditary cystic diseases
(autosomal dominant and recessive polycystic kidney
disease), 14 had tubular disorders including cystinosis,), renal acidosis, use of corticosteroids, hypertension and
age I CKD stage II CKD stage III CKD stage IV+V
11 13 13
% 13.6% 16.0% 16.0%
.1-161.9) 71.3 (65.8-82.8) 43.5 (36.4-5.9) 15.3 (11.7-20.4)
% 0.0% 30.8% 23.1%
% 0.0% 23.1% 23.1%
% 0.0% 7.7% 0.0%
% 72.7% 46.2% 76.9%
% 72.7% 53.8% 46.2%
% 27.3% 15.4% 53.8%
% 36.4% 15.4% 23.1%
% 18.2% 7.7% 7.7%
% 9.1% 15.4% 46.2%
% 0.0% 0.0% 15.4%
% 9.1% 0.0% 46.2%
% 9.1% 30.8% 53.8%
% 36.4% 69.2% 84.6%
% 27.3% 53.8% 92.3%
% 45.5% 15.4% 84.6%
, FGF-23=fibroblast growth factor 23, N=normal.
Table 3 Spearman rank correlational analysis of bone markers and CysC eGFR as well as FGF-23 for the group of all
patients, group of <13 yrs and group of > 13 yrs of age
Correlations of CysC eGFR Correlation coefficient P-value Correlations of FGF-23 Correlation coefficient P-value
❖ All patients FGF-23 −0.4041 <0.0001 ❖ All patients CysC eGFR −0.4041 0.0002
CKD Stage −0.8939 0.7688 CKD Stage 0.4574 < 0.0001
Calcium 0.0332 0.0090 Calcium −0.2020 0.0705
Phosphate −0.2887 0.0083 Phosphate 0.1791 0.1097
Ca*P −0.2914 0.3484 Ca*P 0.1645 0.1422
25-OH Vit D −0.1062 <0.0001 25-OH Vit D 0.0554 0.6253
125(OH)2 Vit D 0.5926 0.0241 125(OH)2 Vit D −0.3455 0.0034
Alk Phosph −0.2603 0.0002 Alk Phosph −0.0858 0.4644
PTH −0.5758 0.0002 PTH 0.3298 0.0039
ionized Ca 0.4278 <0.0001 ionized Ca −0.3301 0.0049
❖ < 13 yrs ❖ < 13 yrs
FGF-23 −0.0798 0.6388 CysC eGFR −0.0798 0.6388
CKD Stage −0.8850 <0.0001 CKD Stage 0.1054 0.5348
Calcium 0.0684 0.6873 Calcium −0.1727 0.3067
Phosphate 0.0649 0.7029 Phosphate −0.0324 0.8490
Ca*P 0.0605 0.7221 Ca*P −0.0440 0.7960
25-OH Vit D −0.3134 0.0589 25-OH Vit D 0.1307 0.4405
125(OH)2 Vit D 0.4281 0.0163 125(OH)2 Vit D 0.1203 0.5193
Alk Phosph −0.2764 0.1080 Alk Phosph −0.1290 0.4602
PTH −0.4727 0.0048 PTH 0.1235 0.4864
ionized Ca 0.4468 0.0081 ionized Ca −0.2085 0.2366
❖ > 13 yrs ❖ > 13 yrs
FGF-23 −0.6330 <0.0001 CysCeGFR −0.6330 <0.0001
CKD Stage −0.8975 <0.0001 CKD Stage 0.7309 <0.0001
Calcium 0.0135 0.9305 Calcium −0.1796 0.2435
Phosphate −0.5558 <0.0001 Phosphate 0.5570 <0.0001
Ca*P −0.5618 <0.0001 Ca*P 0.5343 <0.0001
25-OH Vit D 0.0400 0.7990 25-OH Vit D 0.0032 0.9835
125(OH)2 Vit D 0.6888 <0.0001 125(OH)2 Vit D −0.6306 <0.0001
Alk Phosph −0.4289 0.0058 Alk Phosph 0.2834 0.0764
PTH −0.6071 <0.0001 PTH 0.4747 0.0017
ionized Ca 0.4592 0.0042 ionized Ca −0.5034 0.0015
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mental glomerulosclerosis), 17 had obstructive uropathy,
and 12 had renal dysplasia. The distribution of the
underlying diagnoses is given in Table 1, and while there
was variability among the various CKD stages, this did
not reach statistical significance. Forty four patients had
CKD stage I (Cystatin C-based estimated glomerular filtra-
tion rate (eGFR) >90 mL/min/1.73 m2), 11 patients had
CKD stage II (eGFR 60 to 89.9 mL/min/1.73 m2),
13 patients had CKD stage III (eGFR 30 to 59.9 mL/min/
1.73 m2) and 13 patients had a eGFR <30 mL/min/1.73 m2.
As there were only 6 patients who were on dialysis, CKDstage IV and V were combined. The patients’ characteristics
and median GFR, and the proportion of renal acidosis,
hypertension, and renal osteodystrophy, along with the
respective treatments, are summarized in Table 2. There
was a significant association between the CKD stages and
all parameters in Table 2 except for hypertension, which
may have been confounded by the widespread use of
angiotensin II converting enzyme inhibitors (ACE) or
angiotensin II receptor blockers (ARB). There was also a
progressive decline between GFR stage and 1,25-
dihydroxyvitamin D concentrations, but interestingly, no
changes in the 25-hydroxyvitamin D concentrations. All
Yasin et al. BMC Nephrology 2013, 14:39 Page 5 of 8
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To assess for any correlations between eGFR and other
variables under study for the entire group of patients we
performed the non-parametric spearman rank correlation
analysis. Similar analyses were conducted for the two age
groups of less than 13 years and greater than 13 years of
age. Interestingly, FGF-23 correlated with CysC eGFR
(negatively and significantly) but did not correlate with
either phosphate or calcium phosphate product for the
entire group of patients. This was despite of a similar
eGFR range. For the younger group of age less than
13 years, FGF-23 did not correlate with CysC eGFR, phos-
phate or Ca*P while it correlated negatively and signifi-
cantly with CysC eGFR, positively and significantly with
phosphate and calcium phosphate product for the older
group of patients aging 13 years and above (Figure 1).
CysC eGFR was found to correlate positively and signifi-
cantly with calcium, 1,25-dihydroxyvitamin D levels,
ionized Ca and negatively with FGF-23, phosphate, 25-
hydroxyvitamin D, alkaline phosphate and PTH for the
entire group of patients. CysC eGFR correlations with
bone markers differed when considering age groups. For
the younger group of patients CysC eGFR correlated only
with 1,25-dihydroxyvitamin D levels, PTH and ionized Ca
and for the older group it correlated with FGF-23, Phos-
phate, Ca*P, 1,25-OH Vitamin D levels, alkaline phospha-
tase, PTH and ionized calcium only. X-rays were
performed in 32 of the patients, with 100% of patients
in the two highest stages of CKD. None showed
calcifications. Table 3 summarizes the correlational ana-
lysis results.Figure 1 The relationship between FGF-23 concentrations and
phosphate and Ca* P product. There was a significant correlation
between FGF-23 and both phosphate (top, Spearman r=0.557,
p < 0.0001) and Ca*P (bottom, Spearman r=0.534, p<0.0001) that
followed an exponential growth pattern only in the group of patients
older than 13 years of age. The exponential model could be described
as FGF-23= 29.93 e1.151P in the case of phosphate and FGF-23= 38.15
e 0.4625Ca*P in the case of calcium phosphate product with regression
coefficients of 0.8758 and 0.7819, respectively.Total calcium dropped slightly in CKD stage IV and V,
while phosphate rose to abnormal values in CKD stage
IV and V as did the intact PTH concentrations. However,
noticeably abnormal values of 1,25-dihydroxyvitamin D
and FGF-23 concentrations were already noted in patients
with CKD stage III. The median values of calcium,
phosphate, 25-hydroxyvitamin D, 1,25 dihydroxyvitamin
D, alkaline phosphatase, intact PTH and FGF-23
concentrations are given in Table 4. While one cannot ex-
trapolate from a cross-sectional study on the longitudinal
evolution of mineral bone disease laboratory markers, it
appears that the drop in the 1,25-dihydroxyvitamin D
concentrations is more prevalent in patients with CKD
stage III when compared to all other biochemical bone
markers. FGF-23 correlated significantly with CysC
(Figure 2 and Table 4).
Discussion
The objective of the current study was to describe the
relationship of FGF-23 values to Ca*P in children and
young adults with CKD and no evidence of vascular
calculations. The prevalence of complications worsened
with CKD stage, similar to our previously published
study on 366 children [23]. However, the previous study
did not include data on FGF-23 and a detailed look at
markers of bone mineral disease in CKD patients. The
novel finding is the correlation of FGF-23 levels with the
Ca*P product, which has not previously been reported in
children, but interestingly only in adolescents and young
adults.
Many of the relationships described in this manuscript
have been reported previously by Magnusson et al. [24],
Bacchetta et al. [17] and Srivaths et al. [18]. Magnusson
et al’s study is the only prospective study, but may have
been limited by the study’s small sample size (n=13).
Several other studies have explored the relationship be-
tween FGF-23 and the correlation with other bone
markers in paediatric CKD patients [14,25-27], but they
have looked at smaller and more limited population of
CKD patients – for instance, advanced CKD patients
[25] or renal transplant patients [27,28]. This current
study is more comprehensive, including CKD patients
from all stages and varying aetiologies, and examines
FGF-23 and its relationship with other bone markers
across CKD stage.
The inverse relationship between FGF-23 and eGFR
has been demonstrated in many studies, both in the
pediatric and adult population [1,14,24,29]. The elevated
FGF-23 levels observed in CKD have been explained by
both increasing production by altered osteocyte function
[3,19] and by accumulation secondary to decreased renal
clearance, as FGF-23 is a low molecular weight protein
that is freely filtered across the glomeruli [14]. The exact
contribution of each to this process is unknown.
Table 4 Bone parameters and CKD stage
CKD stage Calcium
[mmol/L]
Phosphate
[mmol/L]
25-OH vitamin D
[nmol/L]
1,25 (OH)2 vitamin
D [pmol/L]
Alkaline
phosphatase [U/L]
intact PTH
[pmol/L]
FGF-23
[pg/mL]
CKD stage
I
2.32 (2.2-2.4) 1.27 (1.1-1.4) 61 (48.5-86.5) 82 (70.5-100.5) 153 (85.0-216.5) 3.8 (2.8-4.8) 39.4 (30.9-47.2)
CKD stage
II
2.39 (2.3-2.4) 1.19 (1.2-1.4) 45 (44–91) 57 (46–73.5) 153 (96–283) 4.4 (3.3-7.8) 45.2 (24.3-51.6)
CKD stage
III
2.36 (2.3-2.4) 1.22 (1.2-1.3) 64 (47–101) 53.5 (41–64.2) 218 (122.5-254) 8.8 (7–9.3) 52.8 (28.9 – 102.8)
CKD stage
IV+V
2.22 (2.1-2.4) 2.06 (1.7-2.3) 58.5 (47.5-127.2) 17 (12–32.5) 188 (102–261) 44.4 (9.7-79.1) 461.1 (158.4 – 666.8)
Data are given in median and interquartile range (25th and 75th percentile).
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the effect of the Ca*P on the FGF-23 concentrations,
which the literature only demonstrated in adults [8,10].
Our data would suggest that FGF-23 is associated with
calcium phosphate metabolism disorders, and not neces-
sarily with aortic calcifications, although we have to
acknowledge the limitation that only 32 patients had a
chest x-ray. With this limitation, our data would support
the interpretation by Kojima et al. [9]. Of course it is notFigure 2 There was a significant correlation (Spearman r=0.404,
p<0.0001) between both markers, FGF-23 and CysC, for the
whole group of patients that followed an exponential growth
pattern. The exponential model could be described as FGF-23=
27.10 e 0.5759CysC with a regression coefficient of 0.6660.very surprising that FGF-23 levels correlated with Ca*P,
as they correlated with phosphate, whereas calcium
levels changed only mildly with increasing FGF-23 levels.
Nonetheless, Ca*P has emerged as a key risk factor for
cardiovascular calcifications, especially when assessing
the area under the time concentration curve over time.
FGF-23 levels may provide an additional marker of the
morbidity and mortality of Ca*P as it is associated with
endothelial dysfunction and cardiovascular out-
come [13].
The main limitation of this study was the cross-
sectional design. Although we demonstrated associations
between several bone markers – including FGF-23 –
and glomerular filtration rate, these associations may
not be causative. A prospective, longitudinal study is
required to further delineate the relationship between
GFR and CKD-MBD parameters. Another limitation of
our study was the use of estimated glomerular filtration
rate by Cystatin C, rather than the use of GFR measure-
ment by inulin, although the latter is time-consuming
and not practical or well-suited to clinical practice and
this cross-sectional design. Perhaps the most significant
limitation is the lack of urinary phosphate measurements
for the calculation of Tp/GFR, which may already be
reduced at earlier stages of CKD than serum phosphate
concentrations. Another limitation forms the fact that a
small subset of patients received steroids, which may
affect FGF-23 levels [17]. We also did not assess patients
on their dietary phosphorus intake, which can contribute
to phosphorus retention and bone mineral disroders
with decreasing GFR.
Conclusion
In conclusion, the current study describes FGF-23 in re-
lationship to other CKD-MBD parameters in 81 CKD
patients. As expected, the prevalence of abnormal
findings and medians for 1,25-dihydroxyvitamin D,
serum phosphate, PTH, serum calcium and FGF-23
changed with worsening kidney function. The study
confirms the association of FGF-23 levels with the Ca*P
only for patients older than 12 years of age.
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